Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Overweight
- Symbol (ZEAL)
- Company Zealand Pharma A/S
- Price $17.59
- Changes Percentage (0%)
- Change -$0
- Day Low $17.47
- Day High $18.07
- Year High $32.12
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $29.00
- High Stock Price Target $32.00
- Low Stock Price Target $26.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-1,018,149,000
Income Statement
Quarterly
Annual
Latest News of ZEAL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
New Zealand reclaims world record for largest mass haka
New Zealand reclaimed the world record for the largest mass haka with over 6,000 participants performing the Maori war dance at Eden Park. The traditional challenge involved vigorous movements and rhy...
By CBS News | 20 hours ago -
New Zealand brave the storm, but Sri Lanka close in on victory in 2nd test
New Zealand put up a strong resistance against Sri Lanka's spin bowlers in the 2nd test in Galle, extending the match to the fourth day after a disastrous collapse in the first innings....
By AP NEWS | 1 day ago -
New Zealand finishes strong to beat Australia 33-13 in 2nd Bledisloe
New Zealand defeated Australia 33-13 in the Bledisloe Cup series, showcasing a strong finish. Despite Australia's early lead, the All Blacks dominated the second half with five tries. The Wallabies st...
By AP NEWS | 2 days ago
